Annual CAPEX
$258.40 M
+$53.70 M+26.23%
31 December 2023
Summary:
Vertex Pharmaceuticals Incorporated annual capital expenditures is currently $258.40 million, with the most recent change of +$53.70 million (+26.23%) on 31 December 2023. During the last 3 years, it has fallen by -$1.40 million (-0.54%). VRTX annual CAPEX is now -0.54% below its all-time high of $259.80 million, reached on 31 December 2020.VRTX CAPEX Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CAPEX
$67.70 M
-$9.00 M-11.73%
30 September 2024
Summary:
Vertex Pharmaceuticals Incorporated quarterly capital expenditures is currently $67.70 million, with the most recent change of -$9.00 million (-11.73%) on 30 September 2024. Over the past year, it has increased by +$27.10 million (+66.75%). VRTX quarterly CAPEX is now -72.75% below its all-time high of $248.40 million, reached on 31 March 2024.VRTX Quarterly CAPEX Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CAPEX
$508.90 M
+$27.10 M+5.62%
30 September 2024
Summary:
Vertex Pharmaceuticals Incorporated TTM capital expenditures is currently $508.90 million, with the most recent change of +$27.10 million (+5.62%) on 30 September 2024. Over the past year, it has increased by +$333.00 million (+189.31%). VRTX TTM CAPEX is now at all-time high.VRTX TTM CAPEX Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
VRTX CAPEX Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +26.2% | +66.8% | +189.3% |
| 3 y3 years | -0.5% | +29.2% | +130.4% |
| 5 y5 years | +170.7% | +178.7% | +584.6% |
VRTX CAPEX High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -0.5% | +26.2% | -72.8% | +101.5% | at high | +189.3% |
| 5 y | 5 years | -0.5% | +242.7% | -72.8% | +305.1% | at high | +584.6% |
| alltime | all time | -0.5% | >+9999.0% | -72.8% | +233.6% | at high | +2780.1% |
Vertex Pharmaceuticals Incorporated CAPEX History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $67.70 M(-11.7%) | $508.90 M(+5.6%) |
| June 2024 | - | $76.70 M(-69.1%) | $481.80 M(+3.7%) |
| Mar 2024 | - | $248.40 M(+114.0%) | $464.70 M(+79.8%) |
| Dec 2023 | $258.40 M(+26.2%) | $116.10 M(+186.0%) | $258.40 M(+46.9%) |
| Sept 2023 | - | $40.60 M(-31.9%) | $175.90 M(-7.2%) |
| June 2023 | - | $59.60 M(+41.6%) | $189.50 M(+3.4%) |
| Mar 2023 | - | $42.10 M(+25.3%) | $183.20 M(-10.5%) |
| Dec 2022 | $204.70 M(-12.9%) | $33.60 M(-38.0%) | $204.70 M(-12.1%) |
| Sept 2022 | - | $54.20 M(+1.7%) | $232.90 M(+0.8%) |
| June 2022 | - | $53.30 M(-16.2%) | $231.10 M(+1.5%) |
| Mar 2022 | - | $63.60 M(+2.9%) | $227.70 M(-3.1%) |
| Dec 2021 | $235.00 M(-9.5%) | $61.80 M(+17.9%) | $235.00 M(+6.4%) |
| Sept 2021 | - | $52.40 M(+5.0%) | $220.89 M(-35.7%) |
| June 2021 | - | $49.90 M(-29.6%) | $343.29 M(+10.3%) |
| Mar 2021 | - | $70.90 M(+48.7%) | $311.25 M(+19.8%) |
| Dec 2020 | $259.80 M(+244.6%) | $47.69 M(-72.7%) | $259.80 M(+13.5%) |
| Sept 2020 | - | $174.79 M(+878.5%) | $228.82 M(+192.2%) |
| June 2020 | - | $17.86 M(-8.2%) | $78.31 M(+2.0%) |
| Mar 2020 | - | $19.45 M(+16.4%) | $76.81 M(+1.9%) |
| Dec 2019 | $75.40 M(-21.0%) | $16.71 M(-31.2%) | $75.40 M(+1.4%) |
| Sept 2019 | - | $24.29 M(+48.5%) | $74.34 M(+4.8%) |
| June 2019 | - | $16.36 M(-9.3%) | $70.96 M(-15.7%) |
| Mar 2019 | - | $18.04 M(+15.3%) | $84.21 M(-11.8%) |
| Dec 2018 | $95.45 M(-63.2%) | $15.65 M(-25.2%) | $95.45 M(-22.3%) |
| Sept 2018 | - | $20.91 M(-29.4%) | $122.79 M(-57.6%) |
| June 2018 | - | $29.61 M(+1.1%) | $289.83 M(+4.4%) |
| Mar 2018 | - | $29.28 M(-31.9%) | $277.60 M(+7.0%) |
| Dec 2017 | $259.42 M(+358.6%) | $42.98 M(-77.1%) | $259.42 M(+12.2%) |
| Sept 2017 | - | $187.96 M(+981.6%) | $231.22 M(+304.6%) |
| June 2017 | - | $17.38 M(+56.6%) | $57.15 M(+2.6%) |
| Mar 2017 | - | $11.10 M(-24.9%) | $55.69 M(-1.5%) |
| Dec 2016 | $56.56 M(+24.9%) | $14.79 M(+6.5%) | $56.56 M(+4.2%) |
| Sept 2016 | - | $13.88 M(-12.8%) | $54.30 M(+10.3%) |
| June 2016 | - | $15.92 M(+32.9%) | $49.22 M(+5.3%) |
| Mar 2016 | - | $11.97 M(-4.4%) | $46.72 M(+3.1%) |
| Dec 2015 | $45.30 M(-11.5%) | $12.53 M(+42.4%) | $45.30 M(-4.5%) |
| Sept 2015 | - | $8.80 M(-34.4%) | $47.45 M(-1.0%) |
| June 2015 | - | $13.42 M(+27.1%) | $47.95 M(+3.7%) |
| Mar 2015 | - | $10.56 M(-28.1%) | $46.23 M(-9.7%) |
| Dec 2014 | $51.20 M(-0.4%) | $14.68 M(+57.8%) | $51.20 M(+0.4%) |
| Sept 2014 | - | $9.30 M(-20.5%) | $51.00 M(-15.3%) |
| June 2014 | - | $11.70 M(-24.6%) | $60.21 M(+19.7%) |
| Mar 2014 | - | $15.53 M(+7.3%) | $50.31 M(-2.1%) |
| Dec 2013 | $51.39 M(-27.8%) | $14.47 M(-21.8%) | $51.39 M(-20.9%) |
| Sept 2013 | - | $18.51 M(+928.0%) | $64.97 M(-4.2%) |
| June 2013 | - | $1.80 M(-89.2%) | $67.85 M(-16.8%) |
| Mar 2013 | - | $16.61 M(-40.8%) | $81.59 M(+14.7%) |
| Dec 2012 | $71.14 M(+105.6%) | $28.05 M(+31.1%) | $71.14 M(-1038.9%) |
| Sept 2012 | - | $21.40 M(+37.7%) | -$7.58 M(-60.1%) |
| June 2012 | - | $15.54 M(+152.5%) | -$18.99 M(-152.9%) |
| Mar 2012 | - | $6.16 M(-112.1%) | $35.90 M(+3.8%) |
| Dec 2011 | $34.59 M(-9.1%) | -$50.67 M(-607.5%) | $34.59 M(-65.3%) |
| Sept 2011 | - | $9.98 M(-85.8%) | $99.69 M(-0.8%) |
| June 2011 | - | $70.43 M(+1352.2%) | $100.54 M(+152.6%) |
| Mar 2011 | - | $4.85 M(-66.4%) | $39.79 M(+4.6%) |
| Dec 2010 | $38.05 M(+62.0%) | $14.43 M(+33.2%) | $38.05 M(+22.0%) |
| Sept 2010 | - | $10.83 M(+11.8%) | $31.20 M(+24.2%) |
| June 2010 | - | $9.69 M(+211.4%) | $25.13 M(+25.5%) |
| Mar 2010 | - | $3.11 M(-59.0%) | $20.03 M(-14.8%) |
| Dec 2009 | $23.50 M(-27.0%) | $7.58 M(+59.4%) | $23.50 M(+4.3%) |
| Sept 2009 | - | $4.75 M(+3.6%) | $22.53 M(-20.3%) |
| June 2009 | - | $4.59 M(-30.3%) | $28.28 M(-15.0%) |
| Mar 2009 | - | $6.58 M(-0.5%) | $33.27 M(+3.4%) |
| Dec 2008 | $32.18 M | $6.61 M(-37.1%) | $32.18 M(+4.6%) |
| Sept 2008 | - | $10.51 M(+9.8%) | $30.77 M(+9.1%) |
| June 2008 | - | $9.57 M(+74.2%) | $28.19 M(-11.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2008 | - | $5.49 M(+5.7%) | $31.78 M(-2.0%) |
| Dec 2007 | $32.41 M(-0.0%) | $5.20 M(-34.4%) | $32.41 M(-5.8%) |
| Sept 2007 | - | $7.93 M(-39.7%) | $34.40 M(+2.8%) |
| June 2007 | - | $13.15 M(+114.5%) | $33.47 M(+7.6%) |
| Mar 2007 | - | $6.13 M(-14.7%) | $31.10 M(-4.1%) |
| Dec 2006 | $32.42 M(+91.1%) | $7.19 M(+2.7%) | $32.42 M(+6.7%) |
| Sept 2006 | - | $7.00 M(-35.1%) | $30.37 M(+9.2%) |
| June 2006 | - | $10.78 M(+44.6%) | $27.81 M(+31.3%) |
| Mar 2006 | - | $7.45 M(+44.9%) | $21.17 M(+24.8%) |
| Dec 2005 | $16.96 M(+35.7%) | $5.14 M(+16.0%) | $16.96 M(+8.6%) |
| Sept 2005 | - | $4.43 M(+7.0%) | $15.62 M(+20.0%) |
| June 2005 | - | $4.14 M(+27.9%) | $13.02 M(+1.2%) |
| Mar 2005 | - | $3.24 M(-14.9%) | $12.86 M(+2.9%) |
| Dec 2004 | $12.49 M(-28.0%) | $3.80 M(+107.8%) | $12.49 M(-2.5%) |
| Sept 2004 | - | $1.83 M(-54.0%) | $12.81 M(+37.3%) |
| June 2004 | - | $3.98 M(+38.5%) | $9.33 M(-29.8%) |
| Mar 2004 | - | $2.88 M(-30.2%) | $13.29 M(-23.4%) |
| Dec 2003 | $17.35 M(-55.4%) | $4.12 M(-349.5%) | $17.35 M(-19.1%) |
| Sept 2003 | - | -$1.65 M(-120.8%) | $21.45 M(-39.6%) |
| June 2003 | - | $7.94 M(+14.5%) | $35.50 M(-1.4%) |
| Mar 2003 | - | $6.94 M(-15.6%) | $36.00 M(-7.4%) |
| Dec 2002 | $38.88 M(-27.9%) | $8.22 M(-33.7%) | $38.88 M(-8.3%) |
| Sept 2002 | - | $12.40 M(+46.8%) | $42.38 M(-18.4%) |
| June 2002 | - | $8.45 M(-13.9%) | $51.95 M(-3.2%) |
| Mar 2002 | - | $9.81 M(-16.3%) | $53.66 M(-0.4%) |
| Dec 2001 | $53.90 M(+198.9%) | $11.73 M(-46.6%) | $53.90 M(-0.4%) |
| Sept 2001 | - | $21.97 M(+116.3%) | $54.10 M(+60.0%) |
| June 2001 | - | $10.16 M(+1.1%) | $33.80 M(+33.0%) |
| Mar 2001 | - | $10.05 M(-15.8%) | $25.43 M(+41.0%) |
| Dec 2000 | $18.03 M(+11.3%) | $11.93 M(+614.4%) | $18.03 M(+104.9%) |
| Sept 2000 | - | $1.67 M(-6.1%) | $8.80 M(-31.2%) |
| June 2000 | - | $1.78 M(-33.0%) | $12.80 M(-21.7%) |
| Mar 2000 | - | $2.65 M(-1.7%) | $16.35 M(+1.0%) |
| Dec 1999 | $16.20 M(+105.1%) | $2.70 M(-52.4%) | $16.20 M(+3.2%) |
| Sept 1999 | - | $5.67 M(+6.3%) | $15.70 M(+39.8%) |
| June 1999 | - | $5.33 M(+113.2%) | $11.23 M(+37.0%) |
| Mar 1999 | - | $2.50 M(+13.6%) | $8.20 M(+3.8%) |
| Dec 1998 | $7.90 M(+31.7%) | $2.20 M(+83.3%) | $7.90 M(+3.9%) |
| Sept 1998 | - | $1.20 M(-47.8%) | $7.60 M(+1.3%) |
| June 1998 | - | $2.30 M(+4.5%) | $7.50 M(+27.1%) |
| Mar 1998 | - | $2.20 M(+15.8%) | $5.90 M(-1.7%) |
| Dec 1997 | $6.00 M(+50.0%) | $1.90 M(+72.7%) | $6.00 M(-6.3%) |
| Sept 1997 | - | $1.10 M(+57.1%) | $6.40 M(+8.5%) |
| June 1997 | - | $700.00 K(-69.6%) | $5.90 M(+3.5%) |
| Mar 1997 | - | $2.30 M(0.0%) | $5.70 M(+42.5%) |
| Dec 1996 | $4.00 M(-25.9%) | $2.30 M(+283.3%) | $4.00 M(-25.9%) |
| Sept 1996 | - | $600.00 K(+20.0%) | $5.40 M(-1.8%) |
| June 1996 | - | $500.00 K(-16.7%) | $5.50 M(0.0%) |
| Mar 1996 | - | $600.00 K(-83.8%) | $5.50 M(+1.9%) |
| Dec 1995 | $5.40 M(+184.2%) | $3.70 M(+428.6%) | $5.40 M(+157.1%) |
| Sept 1995 | - | $700.00 K(+40.0%) | $2.10 M(+23.5%) |
| June 1995 | - | $500.00 K(0.0%) | $1.70 M(+54.5%) |
| Mar 1995 | - | $500.00 K(+25.0%) | $1.10 M(-42.1%) |
| Dec 1994 | $1.90 M(+5.6%) | $400.00 K(+33.3%) | $1.90 M(+5.6%) |
| Sept 1994 | - | $300.00 K(-400.0%) | $1.80 M(-5.3%) |
| June 1994 | - | -$100.00 K(-107.7%) | $1.90 M(0.0%) |
| Mar 1994 | - | $1.30 M(+333.3%) | $1.90 M(+5.6%) |
| Dec 1993 | $1.80 M(+20.0%) | $300.00 K(-25.0%) | $1.80 M(-33.3%) |
| Sept 1993 | - | $400.00 K(-500.0%) | $2.70 M(+42.1%) |
| June 1993 | - | -$100.00 K(-108.3%) | $1.90 M(+5.6%) |
| Mar 1993 | - | $1.20 M(0.0%) | $1.80 M(+20.0%) |
| Dec 1992 | $1.50 M(+25.0%) | $1.20 M(-400.0%) | $1.50 M(+400.0%) |
| Sept 1992 | - | -$400.00 K(+100.0%) | $300.00 K(-57.1%) |
| June 1992 | - | -$200.00 K(-122.2%) | $700.00 K(-22.2%) |
| Mar 1992 | - | $900.00 K | $900.00 K |
| Dec 1991 | $1.20 M | - | - |
FAQ
- What is Vertex Pharmaceuticals Incorporated annual capital expenditures?
- What is the all time high annual CAPEX for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated annual CAPEX year-on-year change?
- What is Vertex Pharmaceuticals Incorporated quarterly capital expenditures?
- What is the all time high quarterly CAPEX for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated quarterly CAPEX year-on-year change?
- What is Vertex Pharmaceuticals Incorporated TTM capital expenditures?
- What is the all time high TTM CAPEX for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated TTM CAPEX year-on-year change?
What is Vertex Pharmaceuticals Incorporated annual capital expenditures?
The current annual CAPEX of VRTX is $258.40 M
What is the all time high annual CAPEX for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high annual capital expenditures is $259.80 M
What is Vertex Pharmaceuticals Incorporated annual CAPEX year-on-year change?
Over the past year, VRTX annual capital expenditures has changed by +$53.70 M (+26.23%)
What is Vertex Pharmaceuticals Incorporated quarterly capital expenditures?
The current quarterly CAPEX of VRTX is $67.70 M
What is the all time high quarterly CAPEX for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high quarterly capital expenditures is $248.40 M
What is Vertex Pharmaceuticals Incorporated quarterly CAPEX year-on-year change?
Over the past year, VRTX quarterly capital expenditures has changed by +$27.10 M (+66.75%)
What is Vertex Pharmaceuticals Incorporated TTM capital expenditures?
The current TTM CAPEX of VRTX is $508.90 M
What is the all time high TTM CAPEX for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high TTM capital expenditures is $508.90 M
What is Vertex Pharmaceuticals Incorporated TTM CAPEX year-on-year change?
Over the past year, VRTX TTM capital expenditures has changed by +$333.00 M (+189.31%)